Business Segments Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Berne S.E.
04/09/2026
|
5-day change | 1st Jan Change | ||
| 234.24 CHF | +0.11% |
|
-3.32% | - |
| 21/08 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 20/08 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Life Sciences Tools and Services | ||||||||||
Discovery and Safety Assessment (DSA) | 210.72Cr | 244.73Cr | 261.56Cr | 245.13Cr | 240.29Cr | |||||
CAPEX | -10Cr | -19Cr | -20Cr | -13Cr | -13Cr | |||||
D&A | 18Cr | 18Cr | 17Cr | 19Cr | 17Cr | |||||
Operating Income | 41Cr | 53Cr | 61Cr | 44Cr | 42Cr | |||||
Research Models and Services (RMS) | 69Cr | 74Cr | 79Cr | 83Cr | 85Cr | |||||
CAPEX | -6.12Cr | -4.41Cr | -5.28Cr | -6.41Cr | -3.88Cr | |||||
D&A | 3.91Cr | 4.93Cr | 5.56Cr | 7.38Cr | 8.11Cr | |||||
Operating Income | 17Cr | 16Cr | 15Cr | 11Cr | 4.46Cr | |||||
| - | - | - | - | 240.29Cr | ||||||
| - | - | - | - | 85Cr | ||||||
Pharmaceutical Contract Research Organization | ||||||||||
Manufacturing Solutions (Manufacturing) | 74Cr | 79Cr | 72Cr | 77Cr | 77Cr | |||||
CAPEX | -5.89Cr | -8.71Cr | -5.81Cr | -3.85Cr | -4.14Cr | |||||
D&A | 4.62Cr | 7.3Cr | 8Cr | 9Cr | 14Cr | |||||
Operating Income | 25Cr | 17Cr | 8.83Cr | -7.15Cr | -18Cr | |||||
| - | - | - | - | 77Cr | ||||||
D&A | 29.68L | 21.81L | 38.53L | 68.39L | 79.89L | |||||
Operating Income | - | -21Cr | -23Cr | -26Cr | -26Cr | |||||
Operating Income | -1.77Cr | - | - | - | - | |||||
CAPEX | -72.3L | -39.5L | -26.84L | -19.77L | -59.28L | |||||
Operating Income | -29.68L | - | - | - | - | |||||
Operating Income | -1.84Cr | - | - | - | - | |||||
Operating Income | -2.54Cr | - | - | - | - | |||||
Operating Income | -9.25Cr | - | - | - | - | |||||
Operating Income | -4.3Cr | - | - | - | - |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States (U.S) | 193.44Cr | 234.22Cr | 234.75Cr | 224Cr | 214.18Cr | |||||
Total Assets | 76Cr | 90Cr | 96Cr | 94Cr | 92Cr | |||||
| - | - | - | - | 50Cr | ||||||
Europe | 103.65Cr | 103.21Cr | 107.69Cr | 107.81Cr | 110.27Cr | |||||
Total Assets | 32Cr | 35Cr | 41Cr | 41Cr | 47Cr | |||||
Canada | 34Cr | 40Cr | 49Cr | 48Cr | 50Cr | |||||
Total Assets | 15Cr | 14Cr | 16Cr | 15Cr | 16Cr | |||||
| - | - | - | - | 6.49Cr | ||||||
Asia Pacific | 22Cr | 19Cr | 20Cr | 20Cr | 21Cr | |||||
Total Assets | 6.49Cr | 8.28Cr | 7.46Cr | 6.6Cr | 6.18Cr | |||||
Other | 72.91L | 99.58L | 1.68Cr | 5.28Cr | 6.49Cr | |||||
Total Assets | 21.25L | 19.81L | 3.61Cr | 3.63Cr | 4.22Cr | |||||
| - | - | - | - | 21Cr | ||||||
Japan | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
| - | - | - | - | 214.18Cr | ||||||
| - | - | - | - | 110.27Cr |
Select your edition
All financial news and data tailored to specific country editions
